Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Trekor Metals Limited Common Shares (TGB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Trekor Metals Limited Common Shares — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Trekor Metals Limited Common Shares trades at $8.2 (market cap $3.12B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.4× Trekor Metals Limited Common Shares's market cap, and Trekor Metals Limited Common Shares is more actively traded (3,598,372 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Trekor Metals Limited Common Shares for 4 Days on average.
| SYRE | TGB | |
|---|---|---|
Market Cap | $7.52B | $3.12B |
Volume | 1,441,031 | 3,598,372 |
Sector | Health | Basic Materials |
52-Week High | $108.92 | $9.68 |
52-Week Low | $22.18 | $3.75 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $6.52B | $3.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TGB trades at $8.56, down 1.72% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue projected to grow from $673M in 2025 to $985M in 2026, turning from a net loss of $30M to a $16M profit. Recent copper production announcements highlight operational strength, though valuation metrics remain elevated with a P/E of 406.88. Analyst sentiment is mixed with a 25% buy rating amid balanced hold/sell recommendations.
The outlook for TGB hinges on copper production growth from Gibraltar and Florence mines, supporting revenue expansion and margin improvement. Key risks include execution challenges in mine ramp-ups, commodity price volatility, and high debt levels. While technical indicators suggest near-term upside, the stock's rich valuation requires careful monitoring of earnings delivery against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Trekor Metals Limited Common Shares
Trekor Metals is a mining company focused on copper. It operates the Gibraltar Mine and develops projects involving copper, gold, silver, and niobium.
Read more on TGB →
